†. Frequency Analysis of Amino Acids Resulting from
1. Introduction
Before the era of molecular biology, the methods available for an understanding of gene function were limited. Such studies typically relied on the ability to identify and isolate naturally occurring variants exhibiting a defect in function. Hence, the progress was slow in this regard. The discoveries in the field of microbiology, combined with advances in technology in the later part of 20th century, dramatically changed this scenario. The current molecular biological techniques enable site-directed mutagenesis approaches for generating a gene with a specific amino acid substitution, mutation, or a deletion or for truncating a gene anywhere in a matter of days.
The present review highlights the studies conducted on human immunodeficiency virus type 1 (HIV-1) Vpr, an auxiliary protein associated with virus particles. Vpr contains 96 amino acids, and it is a multifunctional protein. To analyze the contribution of specific residues to protein function and to the cytopathic effects in HIV-1-infected individuals, investigators from several laboratories, including ours, took advantage of a novel approach. Specifically, this approach involved exchange of residues through mutagenesis. The choice of residue was based on the information available regarding the naturally occurring polymorphisms at the level of individual amino acids in Vpr. The results from these studies support a link between polymorphisms in these genes and the disease status of infected individuals, who are known as progressors or non-progressors. In addition the studies have shed light on the structure-function relationship of Vpr.
The Joint United Nations Program on HIV/AIDS (UNAIDS) (2010) reports that the worldwide prevalence of those living with human immunodeficiency virus (HIV) is between 31-35 million as of the end of 2009. Roughly 2.6 million new cases of HIV infection occurred in the same year. That number has likely remained approximately constant. Although the most common route of HIV infection is via sexual contact, the use of contaminated drug paraphernalia, mother-child transmission via pregnancy or breastfeeding, and tainted blood transfusions comprise other means of infection.
The symptomatic outcome of infection is AIDS, usually occurring ~10 years after initial infection. CD4+ T-cell counts drop below 200, and subsequent severe immune dysfunction results. This eventually leads to fatal coinfection by opportunistic pathogens. The advent of highly active retroviral therapy (HAART) in the 1990s led to a drastically improved prognosis for AIDS patients (Peters and Conway, 2011). This triple-drug cocktail controls viremia and allows immune function to recover to nearly uninfected levels, with the caveat of near-perfect patient adherence to a difficult combination of drug regimens. The extremely rigid treatment schedules have resulted in low compliance, leading to the emergence of viruses that exhibit resistance to drugs.
2. Genetic organization of HIV
The causative agents of AIDS have been identified as human immunodeficiency virus types 1 (HIV-1) and 2 (HIV-2). Both HIV-1 and HIV-2 are members of the lentivirus family of retroviruses. HIV-1 is the predominant virus responsible for AIDS throughout the world. The schematic representation of the genome organization of HIV-1 is shown in Figure 1. The genome of HIV-1 codes for two regulatory proteins (Tat and Rev) and four auxiliary proteins (Vif, Vpr Vpu and Nef), in addition to structural proteins Gag, Gag-Pol and Env. The genome organization of HIV-2 is similar to HIV-1. The unique genes are
3. Heterogeneity in the human immunodeficiency virus
Within HIV-1-positive patients, the high error rate of reverse transcription can produce many variants, or quasispecies. After seroconversion to HIV-positive status, the viral loads measure at 10000-50000 viral RNA copies per ml of patient sera during the asymptomatic stage; in the later stages of disease, viral RNA genomes can increase to several million copies per ml (Poropatich and Sullivan, 2011; Tungaturthi et al., 2004). Thus, a high replication rate produces tremendous variation in the viral population within a single patient. The pressures of the host immune response drive the selection of variants from early stages of infection, until the host immune response cannot cope with the viral diversity (Fischer et al., 2010; Wolinsky et al., 1996).
Studies of polymorphisms in a number of the genes of HIV-1 confirm the propensity of the virus to escape host immunity (Fischer et al., 2010; Fischer et al., 2007; Gaschen et al., 2002; Korber et al., 2001). As expected, the antigenic Env protein exhibits the highest mutability. Comparisons of current strains of HIV show a staggering 20% variability within a subtype and up to 35% variability between subtypes (Gaschen et al., 2002). To highlight the problem of this variability in vaccine development, the evolutionary dynamics of influenza virus provides a revealing picture. The influenza genome varies by 1-2% per year, enabling influenza virus escape from polyclonal vaccine responses and necessitating annual vaccine changes (Fischer et al., 2007; Gaschen et al., 2002). Along with intra- and inter-subtype variation in HIV,
The variation in the viral genome throughout the population potentially correlates with the variation among HIV-infected individuals. In the progressor group, in which AIDS develops 10 years after initial infection, CD4+ T-cell counts (the primary marker of AIDS progression) generally fall below 200 cells per μl and causing loss of cell-mediated immunity (Levy, 2009). Along with the normal progressors, several other categories of disease progression exist. Long term non-progressors (LTNPs) and elite controllers (EC) do not receive HAART and do not show the aforementioned clinical signs of AIDS for up to 20 years after infection. CD4+ T-cell counts are maintained to levels above 350 cells per μl and viral loads to under 2000 copies per ml. Viral loads in these groups can range as low as 50-2000 copies per ml (Poropatich and Sullivan, 2011). In rapid progressors (RP), CD4+ T-cell counts generally decline 3-8 years postinfection. Although individual host genetics likely play a role in differential disease progression (Goulder et al., 1997), the presence of multiple quasispecies in patients potentially explains the differences in disease outcome.
4. Polymorphisms in specific HIV-1 genes
Several genes of HIV have a functional role in disease symptoms (Caly et al., 2008; Casartelli et al., 2003; Tolstrup et al., 2006). As Nef downregulates MHC class I antigen presentation involved in generating a cytotoxic T-lymphocyte (CTL) response, polymorphisms in this gene correlate with the LTNP group (Caly et al., 2008; Casartelli et al., 2003; Tolstrup et al., 2006). Similarly the role of Tat as a transactivator of the HIV-1 promoter in the long-terminal-repeat (LTR) region and its genetic heterogeneity suggest a functional role for Tat in disease progression and outcome (Bratanich et al., 1998; Korber et al., 2001). Tat can upregulate LTR-transcriptional activity and thus replication. Cellular and viral transcription increases several hundredfold (Irish et al., 2009) in the presence of Tat. Various Tat proteins isolated from different subtypes show differences in the ability to induce viral and cellular gene transcription (Roof et al., 2002).
The multifunctional Viral Protein R (Vpr), although labeled as an accessory protein, has a vital role in efficient replication of the virus in the non-dividing macrophages and monocytes (Balliet et al., 1994; Connor et al., 1995). Vpr interacts with the Gag protein for packaging into the virion. It remains bound to the preintegration complex (PIC) upon entry of the viral contents into the target cell during infection, most likely aiding PIC entry into the nucleus. It has a highly functional role in replication as a transactivator of the LTR, binding to a number of host transcription factors, such as Sp1 (Sawaya et al., 1998) and TFIIB (Agostini et al., 1999). Extensive studies have shown that coactivation of glucocorticoid receptor by Vpr, resulting in transcription of elements in the promoter regions of the HIV LTR and host genes, enhances viral replication and downregulates host immune responses (Ayyavoo et al., 1997; Hapgood and Tomasicchio, 2010). Vpr also drives apoptosis and G2 cell cycle arrest (Morellet et al., 2009; Pandey et al., 2009; Tungaturthi et al., 2004). The processes enhance immune escape and HIV-1 replication, respectively. As Vpr seems to be essential in the viral life cycle, it is likely that
5. Methods used to generate mutations to study gene regulation
Identifying genes responsible for different phenotypes previously relied on isolating naturally occurring polymorphic genes within the organisms. This process is time-consuming and requires sequencing several isolates to identify the functionally relevant genes. Today there are many different means of following the general path of altering the genotype to observe the phenotype.
5.1. Site-directed mutagenesis
The use of a point mutation to observe the change of function that occurs as a result of a change in structure underscores the majority of studies on the role of polymorphisms in viral and host gene function. One method of generating a targeted mutation in a plasmid construct carrying the gene of interest uses a polymerase chain reaction (PCR) technique. This particular PCR-based method has the advantage of using a high-fidelity polymerase and methylation of DNA by common strains of
PCR will copy the entire parental template. The high-fidelity
6. Structure and function relationship of HIV-1 Vpr
To arrive at the structure of Vpr, several NMR studies have used fragments representing different segments of the Vpr protein. Alternatively the entire Vpr molecule has been analyzed in an appropriate solvent (Morellet et al., 2003; Wecker et al., 2002). The analyses showed a flexible N-terminus with a turn, the first alpha helix, turn, the second alpha helix, turn, the third alpha helix, then a flexible C-terminal domain (Morellet et al., 2003; Wecker et al., 2002). Morellet et al. (2003) used a different solvent, allowing them to “see” the tertiary structure of Vpr. The solvent was better at revealing the hydrophobic parts that are implicated in dimerization and interaction with other proteins (Morellet et al., 2003). Ideally NMR studies of protein structure employ solvents and conditions that approximate physiological conditions. However, the oligomerization property of Vpr makes proper solvation extremely difficult. Several studies have used trifluoroethanol (TFE), a hydrophobic solvent, in different proportions to counteract the interaction of the hydrophobic domains of Vpr, some of which cause Vpr to oligomerize (Engler et al., 2001; Wecker et al., 2002). Across these studies the length of the alpha helices differed due to the proportion of TFE in the solvents used.
Morellet et al. (2003) used CD3CN, a solvent with little hydrophobicity that approaches physiological conditions. This solvent allowed the following structural analysis: alpha helices 1, 2, and 3 (17-33, 38-50, 54-77), a flexible N-terminus (1-16) and a basic C-terminus (78-96). Each helix is amphipathic, containing hydrophobic and hydrophilic residues. The hydrophobic residues can allow for interactions with other proteins, most likely other cellular factors. In the third helix, L60, L67, I74, and I81 can form a leucine zipper (Morellet et al., 2003). The N-terminus consists largely of acidic residues, while the C-terminus consists largely of basic residues, arginine being the most prominent. The 3-D structure established by Morellet et al. (2003; 2009) shows a globular structure, in which hydrophobic interactions between the helices form a lipophilic core. Each of the helices in its amphipathic portions has acidic/basic residues, which are on the external face of the modeled protein. They possibly provide contacts for interactions with other proteins. The folding of the alpha helices entails that hydrophobic portions of the protein face outwards in contact with the solvent. These unfavorable conditions could be ameliorated by binding to cellular partners. Mutational analyses of the protein have found many residues throughout the length of Vpr that maintain the structural integrity (Morellet et al., 2009). Single deletions of Y15 (see Table 1 in the chapter by Figurski et al. for the amino acid codes), K27, and Q44 result in disruption of structure. The helical domains contain residues crucial to structure, especially those that form the hydrophobic core. The basic C-terminal residues also affect structure and stability of Vpr.
6.1. Oligomerization
The property of forming Vpr oligomers has recently come under scrutiny. Zhao et al. (1994) incorporated mutagenesis in their study to elucidate a rough map of residues in Vpr necessary for this function. Deletion of individual residues in the 36-76 region diminishes formation of oligomers. Mutagenesis of individual resides in the leucine-isoleucine motif (60LIRILQQLLFIHFR) in the third helix (amino acids 55-77) reduced the self-associative capacity of Vpr monomers. The residues at position 60, 61, 63, 64, 67, 68, 70, and 74 mutated from leucine or isoleucine to alanine or histidine disrupted binding between monomers (Zhao et al., 1994). The Q44 residue also plays an important role in Vpr oligomerization. Structural analysis of the second alpha helix (amino acids 38-50) reveals a hydrophilic glutamine at the 44th position (Morellet et al., 2009). Deletion of this residue by site-directed mutagenesis disrupted the secondary structure and abolished Vpr—Vpr interaction (Fritz et al., 2008). Fritz et al. (2008) revealed via 3-D modeling that the ΔQ44 mutation destabilizes the formation of the hydrophobic core and the self-interaction of the helices, thus providing an explanation for the inability of such mutants to oligomerize. Although Vpr oligomerization plays a role in other functions, this group did not find a relation between oligomerization and the ability of Vpr to induce apoptosis.
Oligomerization seems necessary for other functions, such as nuclear localization and virion incorporation (Fritz et al., 2008; Fritz et al., 2010; Venkatachari et al., 2010). Venkatachari et al. (2010) hypothesized from a structural model of the oligomerization of Vpr that residues at the predicted helical interfaces contribute to dimerization. Substitution mutagenesis of A30 to leucine abolished dimerization. The authors attributed this to the position of A30 on the external face of the tertiary structure of Vpr, where it likely affects protein-binding. Furthermore, elimination of dimerization of Vpr abolished the ability of the protein to be incorporated into HIV virions. It also diminished its nuclear localization. These results implicate a necessary role of Vpr oligomerization in its incorporation into virions and, by extension, possibly playing a role in the infection of non-replicating immune cells, important targets of HIV-1.
6.2. Nuclear import
The nuclear import of the preintegration complex (PIC) upon entry of the virus enables productive infection to occur in targeted host cells, particularly non-dividing immune cells (
7. G2 cell cycle arrest
The G2 phase of the cellular life cycle serves as a checkpoint for the cell. Factors can halt the cell cycle progression into mitosis in the presence of excessive DNA damage. If these factors do not detect damage, the cell divides; but detection of chromatin disruption will activate factors, such as ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia mutated and Rad-3 related). These factors have downstream effects. Ultimately they hyper-phosphorylate the Cdc2-Cyclin B1 complex, the major controller of cell progression into mitosis. Hyper-phosphorylation inactivates Cdc2-Cyclin B1 to prevent cell division. This process arrests the cell in the G2 phase (Morellet et al., 2009; Pandey et al., 2009; Sherman et al., 2002). Vpr expression in various cell types leads to G2 cell cycle arrest. It does so through increased expression of p21 through the p53 pathway, a major regulator of progression through the G2 and M phases (Chowdhury et al., 2003). Vpr seems to act synergistically with p53, perhaps inducing transcription of p21 through its own transactivation mechanisms. Although the purpose of the G2 arrest function of the virus is debatable, evidence suggests that it enhances transcription from the viral promoter, the long terminal repeat (LTR) of the HIV genome (Goh et al., 1998). One mechanism by which this occurs is through enhancing transactivation of the LTR in CD4+ T-cells via Vpr itself. Vpr binds to other host transcription factors, which bind to sites in the LTR, allowing viral transcription to occur. This effect is enhanced during G2 arrest (Gummuluru and Emerman, 1999).
The C-terminal portion of the protein seems to be essential for induction of cell cycle arrest. Zhou and Ratner (2000) showed that the phosphorylated S79 residue is necessary for this function. Their mutagenesis study of substituting alanine for serine eliminated phosphorylation at this residue and abolished arrest in the G2 phase, correlating the two functions with each other. Furthermore, the mutation of G75A impaired G2 cell cycle arrest, as shown by Mahalingam et al. (1997). DeHart et al. (2007) proposed that Vpr hijacks the ubiquitin/proteasome pathway. One of the functions of this pathway is to target proteins for degradation and to cause G2 cell cycle arrest when needed. In their model, Vpr binds DCAF1, a subunit of the Cullin-4 E3 ubiquitin ligase, to lead to ubiquitination of an unknown host factor involved in halting the cell cycle progression. Change of Q65 to arginine eliminated this binding and impaired G2 cell cycle arrest. However, the group also generated an R80A substitution that also disrupted G2 cell cycle arrest; but this mutant Vpr maintained the ability to bind DCAF1. The authors interpreted these results to indicate that binding DCAF1 is necessary, but not sufficient, to cause G2 cell cycle arrest. A recent study revealed a highly conserved motif in the C-terminus (79SRIG82), in which mutations that change each amino acid prohibit G2 cell cycle arrest. This study corroborates previous evidence of the functional role of the R80 residue (DeHart et al., 2007; Maudet et al., 2011). Mutagenesis studies using the substitutions R73A and R80A eliminated the induction of p21 transcription, which is necessary for induction of G2 cell cycle arrest.
While the C-terminal portion of Vpr seems necessary for G2 cell cycle arrest, several of the previously cited studies and others revealed that certain N-terminal residues may be indispensable for this function. At least two studies indicated that mutagenesis of A30 to leucine also abolished cell cycle arrest and reduced the transcription of p21 (Chowdhury et al., 2003; Mahalingam et al., 1997). As noted above, A30L eliminated oligomerization, which suggests a correlation between the functions of oligomerization and G2 cell cycle arrest. Also K27M (methionine for lysine 27) another substitution in the first helix, disables the induction of G2 cell cycle arrest. Overall the evidence indicates that N-terminal and C-terminal moieties influence the conformational binding determinants of Vpr involved in G2 cell cycle arrest.
8. Apoptosis
Apoptosis (programmed cell death) functions as a primary means of maintaining homeostasis among cells. Apoptosis can occur as a result of irreparable DNA damage or by disruption of essential cellular processes, such as transcription or translation. Infection by HIV disrupts the normal induction of apoptosis. Despite disrupting apoptosis, infected CD4+ T-cells still die (Groux et al., 1992; Jamieson et al., 1997). However, bystander cells not directly infected by HIV-1, such as CD8+ T-cells, neurons and other cell types, undergo apoptosis (Finkel et al., 1995; Zhang et al., 2003). The Vpr protein was shown to play a key role in the induction of apoptosis in several
Correlation of the function of Vpr that influences apoptosis with the function that promotes G2 cell cycle arrest remains a complicated affair. Jacquot et al. (2007) reported experiments that indicated a correlation. The group generated several Vpr substitution mutants that abolished both cell cycle arrest and apoptosis. Their results were consistent with the model of G2 cell cycle arrest leading to the induction of apoptosis. Mutants K27M and A30L in the N-terminus of Vpr and R80A and R90K in the C-terminus disabled cytostatic capacity and reduced apoptosis in a T-cell line. However, Bolton and Lenardo (2007) reported that the Vpr with the R80A substitution attenuated apoptotic effects in Jurkat cells, although it remained G2 arrest-capable. Also Maudet et al. (2011) showed that the apoptotic function of alanine mutants in the 79SRIG82 motif, including R80, and the K27M substitution mutant remained intact without G2 cell cycle arrest. The evidence from such mutagenesis studies may indicate that, although G2 cell cycle arrest leads to apoptosis, a G2 cell cycle arrest-independent apoptotic pathway exists.
Interestingly, Maudet et al. (2011) showed that the ability of Vpr to bind DCAF1 is not only necessary for induction of G2 cell cycle arrest, but for apoptosis as well. The substitution mutant Q65R eliminated DCAF1 binding, abolishing cell death. The S79A and K27M mutants retained their ability to cause apoptosis while losing G2 arrest function. Mutagenesis was done to produce the double mutants K27M/Q65R and S79A/Q65R. These mutants eliminated the G2 cell cycle arrest-independent induction of apoptosis. As DCAF1 is essential for the targeting of proteins to the proteasome, the authors propose a model in which Vpr binds DCAF1 at a region containing the Q65 residue and functions as an adaptor to the ubiquitin/proteasome complex. Their mutagenesis studies suggest that Vpr contains two different binding domains that interact with two separate, and as yet unidentified, host targets. This ostensibly leads to ubiquitination and subsequent degradation of these proteins. Degradation of target 1 leads to G2 cell cycle arrest, and ubiquitination of target 2 leads to apoptosis. However, these targets have yet to be identified. The model implies complex pathways.
9. Vpr polymorphisms across subtypes
A phylogenetic analysis of
Residue conserved In the LTNP alignment (n=177) | ||||
2 | E | 174 | E | 101 |
3 | Q | 168 | Q | 96 |
4 | A | 175 | A | 96 |
5 | P | 176 | P | 101 |
6 | E | 166 | E | 100 |
7 | D | 170 | D | 91 |
8 | Q | 175 | Q | 101 |
9 | G | 165 | G | 102 |
10 | P | 176 | P | 102 |
11 | Q | 174 | Q | 98 |
12 | R | 167 | R | 102 |
13 | E | 168 | E | 100 |
14 | P | 177 | P | 100 |
15 | Y | 172 | Y | 96 |
16 | N | 158 | N | 96 |
17 | E | 169 | E | 96 |
18 | W | 175 | W | 102 |
19 | T | 153 | T | 93 |
20 | L | 173 | L | 102 |
21 | E | 174 | E | 102 |
22 | L | 170 | L | 95 |
23 | L | 170 | L | 102 |
24 | E | 169 | E | 100 |
25 | E | 172 | E | 102 |
26 | L | 173 | L | 101 |
27 | K | 172 | K | 102 |
28 | N | 74 | S | 40 |
29 | E | 171 | E | 101 |
30 | A | 170 | A | 102 |
31 | V | 171 | V | 101 |
32 | R | 167 | R | 100 |
33 | H | 174 | H | 101 |
34 | F | 174 | F | 101 |
35 | P | 175 | P | 101 |
36 | R | 171 | R | 88 |
37 | I | 50 | V | 51 |
38 | W | 174 | W | 101 |
39 | L | 175 | L | 99 |
40 | H | 175 | H | 88 |
41 | S | 89 | G | 71 |
42 | L | 171 | L | 101 |
43 | G | 171 | G | 101 |
44 | Q | 175 | Q | 101 |
45 | H | 118 | H | 72 |
46 | I | 174 | I | 101 |
47 | Y | 173 | Y | 101 |
48 | E | 146 | E | 92 |
49 | T | 174 | T | 98 |
50 | Y | 175 | Y | 101 |
51 | G | 169 | G | 101 |
52 | D | 175 | D | 100 |
53 | T | 175 | T | 100 |
54 | W | 174 | W | 98 |
55 | A | 123 | A | 58 |
56 | G | 171 | G | 100 |
57 | V | 174 | V | 100 |
58 | E | 164 | E | 97 |
59 | A | 166 | A | 96 |
60 | I | 149 | I | 62 |
61 | I | 167 | I | 96 |
62 | R | 170 | R | 96 |
63 | I | 136 | I | 53 |
64 | L | 176 | L | 99 |
65 | Q | 173 | Q | 97 |
66 | Q | 174 | Q | 96 |
67 | L | 174 | L | 98 |
68 | L | 174 | L | 82 |
69 | F | 176 | F | 100 |
70 | I | 145 | I | 93 |
71 | H | 173 | H | 100 |
72 | F | 174 | F | 99 |
73 | R | 174 | R | 100 |
74 | I | 172 | I | 97 |
75 | G | 158 | G | 95 |
76 | C | 171 | C | 99 |
77 | R | 106 | R | 52 |
78 | H | 174 | H | 100 |
79 | S | 175 | S | 98 |
80 | R | 172 | R | 99 |
81 | I | 171 | I | 97 |
82 | G | 174 | G | 100 |
83 | I | 171 | I | 99 |
84 | T | 99 | T | 66 |
85 | R | 111 | Q | 40 |
86 | Q | 143 | Q | 83 |
87 | R | 168 | R | 94 |
88 | R | 168 | R | 97 |
89 | A | 140 | A | 83 |
90 | R | 169 | R | 95 |
91 | N | 170 | N | 56 |
92 | G | 171 | G | 57 |
93 | A | 153 | A | 55 |
94 | S | 162 | S | 51 |
95 | R | 173 | R | 58 |
An approach using site-directed mutagenesis to study these substitutive polymorphisms will link these variants to possible effects on Vpr function and to the long-term non-progressor and rapid progressor statuses.
10. Mutagenesis studies in the context of disease progression and pathogenesis
Wang et al. (1996) analyzed sequences of the
Caly et al. (2008) found a mutation, F72L, in several
However, given the complexities of the interrelated pathways by which Vpr induces apoptosis, as revealed by the mutagenesis studies detailed above, it is likely that the two published studies explain only a fraction of the causative factors behind the progression of HIV disease. Many questions need to be answered before the role of Vpr in disease induction is clear.
References
- 1.
Agilent ( QuikChange II Site-Directed Mutagenesis Kit: Instruction Manual, Revision C.2010 - 2.
Agilent ( PfuUltra High-Fidelity DNA Polymerase AD, Revision B.2011 - 3.
Agostini I J. M Navarro M Bouhamdan K Willetts F Rey B Spire R Vigne andR Pomerantz J Sire 1999 The HIV-1 Vpr Co-activator Induces a Conformational Change in TFIIB 450 3 235 239 - 4.
Ayyavoo V A Mahboubi S Mahalingam R Ramalingam S Kudchodkar W Williams andD Green D Weiner 1997 HIV-1 Vpr Suppresses Immune Activation and Apoptosis through Regulation of Nuclear Factor Kappa B. 3 10 1117 23 - 5.
Balliet J. W D. L Kolson G Eiger F. M Kim K. A Mcgann andA Srinivasan R Collman 1994 Distinct Effects in Primary Macrophages and Lymphocytes of the Human Immunodeficiency Virus Type 1 Accessory Genes Vpr, Vpy, and Nef: Mutational Analysis of a Primary HIV-1 Isolate. 200 2 623 631 - 6.
andBolton D. L M. J Lenardo 2007 Vpr Cytopathicity Independent of G2/M Cell Cycle Arrest in Human Immunodeficiency Virus Type 1-Infecteed CD4+ T Cells." Journal of Virology81 17 8878 8890 - 7.
Bratanich A. C C Liu J. C Mcarthur T Fudyk J. D Glass S Mittoo andG. A Klassen C Power 1998 Brain-Derived HIV-1 Tat Sequences from AIDS patients with Dementia Show Increased Molecular Heterogeneity. 4 4 387 393 - 8.
Bukrinsky M. I N Sharova M. P Dempsey T. L Stanwick A. G Bukrinskaya andS Haggerty M Stevenson 1992 Active Nuclear Import of Human Immunodeficiency virus type 1 preintegration complexes. Proceedings of the National Academy of Science89 14 6580 6584 - 9.
Caly L N Saksena andS Piller D Jans 2008 Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor 67 EOF - 10.
Doria (Casartelli N G Di Matteo M Potesta P Rossi andM 2003 CD4 and Major Histocompatibility Complex Class I Downregulation by the Human Immunodeficiency Virus Type 1 Nef Protein in Pediatric AIDS Progression J. Virol.77 21 11536 11545 - 11.
Chen M R. T Elder M. G. O Gorman L Selig R Benarous andA Yamamoto Y Zhao 1999 Mutational analysis of Vpr-induced G2 arrest, nuclear localization, and cell death in fission yeast Journal of Virology73 4 3236 3245 - 12.
Chowdhury I. H X. -F Wang N. R Landau M. L Robb V. R Polonis andD. L Birx J. H Kim 2003 HIV-1 Vpr Activates Cell Cycle Inhibitor 21 Waf1/Cip1: A Potential Mechanism of G2/M Cell Cycle Arrest - 13.
Cohen E. A G Dehni andJ. G Sodroski W. A Haseltine 1990 Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J. Virol.64 6 3097 3099 - 14.
Connor R. I B. K Chen andS Choe N. R Landau 1995 Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes. 206 2 935 944 - 15.
Dehart J E Zimmerman O Ardon C Monteiro-filho andE Arganaraz V Planelles 2007 HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system. 57 EOF - 16.
Engler A andT Stangler D Willbold 2001 Solution structure of human immunodeficiency virus type 1 Vpr(13-33) peptide in micelles. 268 2 389 395 - 17.
Finkel T. H G Tudor-williams N. K Banda M. F Cotton T Curiel C Monks T. W Baba andR. M Ruprecht A Kupfer 1995 Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. 1 2 129 134 - 18.
Fischer W V. V Ganusov E. E Giorgi P. T Hraber B. F Keele T Leitner C. S Han C. D Gleasner L Green C. -C Lo A Nag T. C Wallstrom S Wang A. J Mcmichael B. F Haynes B. H Hahn A. S Perelson P Borrow G. M Shaw andT Bhattacharya B. T Korber 2010 Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. e12303 EOF - 19.
Fischer W S Perkins J Theiler T Bhattacharya K Yusim R Funkhouser C Kuiken B Haynes N. L Letvin B. D Walker andB. H Hahn B. T Korber 2007 Polyvalent Vaccines for Optimal Coverage of Potential T-Cell Epitopes in Global HIV-1 Variants. 13 1 100 106 - 20.
Fritz J. V P Didier J. -P Clamme E Schaub D Muriaux C Cabanne N Morellet S Bouaziz J. -L Darlix andY Mely H. d Rocquigny 2008 Direct Vpr-Vpr Interaction in Cells Monitored by two Photon Fluorescence Correlation Spectroscopy and Fluroescence Lifetime Imaging." Retrovirology 5(87). - 21.
Fritz J. V D Dujardin J Godet P Didier J. D Mey J. -L Darlix andY Mely H. d Rocquigny 2010 HIV-1 Vpr Oligomerization but Not That of Gag Directs the Interaction between Vpr and Gag. 84 3 1585 1596 - 22.
Gaschen B J Taylor K Yusim B Foley F Gao D Lang V Novitsky B Haynes B. H Hahn andT Bhattacharya B Korber 2002 Diversity Considerations in HIV-1 Vaccine Selection 296 5577 2354 2360 - 23.
Ge Y. C B Wang D. E Dwyer S. -H Xiang andA. L Cunningham N Saksena 1996 Sequence Note: Length Polymorphism of the Viral Protein R of Human Immunodeficiency Virus Type 1 Strains 12 4 351 354 - 24.
Goh W. C M. E Rogel C. M Kinsey S. F Michael P. N Fultz M. A Nowak andB. H Hahn M Emerman 1998 HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo. 4 1 65 71 - 25.
Goulder P. J. R R. E Phillips R. A Colbert S Mcadam G Ogg M. A Nowak P Giangrande G Luzzi B Morgana A Edwards andA. J Mcmichael S Rowland-jones 1997 Late Escape from an Immunodominant Cytotoxic T-Lymphocyte Response Associated with Progression to AIDS. 3 2 212 217 - 26.
Groux H G Torpier D Monte Y Mouton andA Capron J. C Ameisen 1992 Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. Journal of Experimental Medicine175 2 331 340 - 27.
andGummuluru S M Emerman 1999 Cell Cycle- and Vpr-Mediated Regulation of Human Immunodeficiency Virus Type 1 Expression in Primary and Transformed T-Cell Lines. J. Virol.73 7 5422 5430 - 28.
andHapgood J. P M Tomasicchio 2010 Modulation of HIV-1 Virulence Via the Host Glucocorticoid Receptor: Towards Further Understanding the Molecular Mechanism of HIV-1 Pathogenesis." 155 7 1009 1019 - 29.
HIV/AIDS T. J. U. N. P. o. (2010 Global Report: UNAIDS Report on the Global AIDS Epidemic 2010, J oint United Nations Programme on HIV/AIDS (UNAIDS). - 30.
Irish B. P Z. K Khan P Jain M. R Nonnemacher V Pirrone S Rahman N Rajagopalan J. B Suchitra andK Mostoller B Wigdahl 2009 Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A review 5 3 231 258 - 31.
Jacotot E L Ravagnan M Loeffler K. F Ferri H. L. A Vieira N Zamzami P Costantini S Druillennec J Hoebeke J. P Briand T Irinopoulou E Daugas S. A Susin D Cointe Z. H Xie J. C Reed andB. P Roques G Kroemer 2000 The HIV-1 Viral Protein R Induces Apoptosis via a Direct Effect on the Mitochondrial Permeability Transition Pore. 191 1 33 46 - 32.
Pancino and S. Benichou (Jacquot G E Le Rouzic A David J Mazzolini J Bouchet S Bouaziz F Niedergang G 2007 Localization of HIV-1 Vpr to the nuclear envelope: Impact on Vpr functions and virus replication in macrophages. 84 EOF - 33.
Jamieson B. D C. H Uittenbogaart andI Schmid J. A Zack 1997 High viral burden and rapid CD4+ cell depletion in human immunodeficiency virus type 1-infected SCID-hu mice suggest direct viral killing of thymocytes in vivo. 71 11 8245 8253 - 34.
Korber B B Gaschen K Yusim R Thakallapally andC Kesmir V Detours 2001 Evolutionary and immunological implications of contemporary HIV-1 variation 58 1 19 42 - 35.
Kuiken C. L M. T. E Cornelissen F Zorgdrager S Hartman andA. J Gibbs J Goudsmit 1996 Consistent risk group-associated differences in human immunodeficiency virus type 1 vpr, vpu and Journal of General Virology 77(4):3 sequences despite independent evolution.783 EOF 92 EOF - 36.
Levy J. A 2009 HIV Pathogenesis: 25 Years of Progress and Persistent Challenges. AIDS23 2 147 160 - 37.
Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis."Lum J. J O. J Cohen Z Nie J. G Weaver T. S Gomez X. -J Yao D Lynch A. A Pilon N Hawley J. E Kim Z Chen M Montpetit J Sanchez-dardon andE. A Cohen A. D Badley 2003 Vpr R 111 10 1547 1554 - 38.
Macreadie I. G L. A Castelli D. R Hewish A Kirkpatrick andA. C Ward A. A Azad 1995 A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects." Proceedings of the National Academy of Sciences92 7 2770 2774 - 39.
Mahalingam S V Ayyavoo M Patel andT Kieber-emmons D. B Weinter 1997 Nuclear Import, Virion Incorporation, and Cell Cycle Arrest/Differentiation Are Mediated by Distinct Functional Domains of Human Immunodeficiency Virus Type 1 Vpr." Journal of Virology71 9 6339 6347 - 40.
Margottin-Goguet and C. Transy (Maudet C M Bertrand E Le Rouzic H Lahouassa D Ayinde S Nisole C Goujon A Cimarelli F 2011 Molecular Insight into How HIV-1 Vpr Protein Impairs Cell Growth through Two Genetically Distinct Pathways. Journal of Biological Chemistry286 27 23742 23752 - 41.
Morellet N S Bouaziz andP Petitjean B. P Rogues 2003 NMR Structure of the HIV-1 Regulatory Protein VPR 327 1 217 227 - 42.
Morellet N andB. P Roques S Bouaziz 2009 Structure-Function Relationship of Vpr: Biological Implications. 7 2 184 210 - 43.
Nitahara-kasahara Y M Kamata T Yamamoto X Zhang Y Miyamoto K Muneta S Iijima Y Yoneda andY Tsunetsugu-yokota Y Aida 2007 Novel Nuclear Import of Vpr Promoted by Importin {alpha} Is Crucial for Human Immunodeficiency Virus Type 1 Replication in Macrophage s." J. Virol.81 10 5284 5293 - 44.
notation for amino acid sequences. Tentative rules." BiochemistryNomenclature I I. C. o. B. ( 1968 AOne-letter 7 8 2703 2705 - 45.
Pandey R. C D Datta R Mukerjee A Srinivasan andS Mahalingam B. E Sawaya 2009 HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective. 7 2 114 128 - 46.
Pandori M N Fitch H Craig D Richman andC Spina J Guatelli 1996 Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein J. Virol.70 7 4283 4290 - 47.
andPeters B. S K Conway 2011 Therapy for HIV: Past, Present, and Future. 23 1 23 27 - 48.
Popov S M Rexach L Ratner andG Blobel M Bukrinsky 1998 Viral Protein R Regulates Docking of the HIV-1 Preintegration Complex to the Nuclear Pore Complex Journal of Biological Chemistry273 21 13347 13352 - 49.
andPoropatich K D. J Sullivan 2011 Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. Journal of General Virology92 2 247 268 - 50.
Roof P M Ricci P Genin M. A Montano M Essex M. A Wainberg andA Gatignol J Hiscott 2002 Differential Regulation of HIV-1 Clade-Specific B, C, and E Long Terminal Repeats by NF-?B and the Tat Transactivator 296 1 77 83 - 51.
Sawaya B. E K Khalili W. E Mercer andL Denisova S Amini 1998 Cooperative Actions of HIV-1 Vpr and Journal of Biological Chemistry 273(32): 20052-20057.53 Modulate Viral Gene Transcription. - 52.
Sherman M. P C. M. C De Noronha M. I Heusch andS Greene W. C Greene 2001 Nucleocytoplasmic Shuttling by Human Immunodeficiency Virus Type 1 Vpr J. Virol.75 3 1522 1532 - 53.
Sherman M. P C. M. C. D Noronha andS. A Williams W. C Greene 2002 Insights into the Biology of HIV-1 Viral Protein R. 21 9 679 688 - 54.
Somasundaran M M Sharkey B Brichacek K Luzuriaga M Emerman andJ. L Sullivan M Stevenson 2002 Evidence for a cytopathogenicity determinant in HIV-1 Vpr Proceedings of the National Academy of Sciences99 14 9503 9508 - 55.
Stewart S. A B Poon andJ. B Jowett I. S Chen 1997 Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. Journal of Virology71 7 5579 5592 - 56.
Strebel K 2003 Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS 17(4): S25 S34. - 57.
Tolstrup M A. L Laursen J Gerstoft F. S Pedersen andL Ostergaard M Duch 2006 Cysteine 138 Mutation in HIV-1 Nef from Patients with Delayed Disease Progression. Sex Health3 4 281 286 - 58.
Tungaturthi P. K B. E Sawaya V Ayyavoo andR Murali A Srinivasan 2004 HIV-1 Vpr: Genetic Diversity and Functional Features from the Perspective of Structure. 23 4 207 222 - 59.
Venkatachari N. J L. A Walker O Tastan T Le T. M Dempsey Y Li N Yanamala A Srinivasan J Klein-seetharaman andR. C Montelaro V Ayyavoo 2010 Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles Virology Journal 7(119). - 60.
Wang B Y. C Ge P Palasanthiran S. -H Xiang J Ziegler D. E Dwyer C Randle D Dowton andA Cunningham N. K Saksena 1996 Gene Defects Clustered at the C-Terminus of the vpr Gene of HIV-1 in Long-Term Nonprogressing Mother and Child Pair:In VivoEvolution of vpr Quasispecies in Blood and Plasma 223 1 224 232 - 61.
Wecker K N Morellet andS Bouaziz B. P Rogues 2002 NMR Structure of the HIV-1 Regulatory Protein Vpr in H2O/trifluoroethanol. Comparison with the Vpr N-terminal (1-51) and C-terminal (52-96) domains." 269 15 3779 3788 - 62.
Wolinsky S. M B. T. M Korber A. U Neumann M Daniels K. J Kunstman A. J Whetsell M. R Furtado Y Cao D. D Ho andJ. T Safrit R. A Koup 1996 Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection 272 5261 537 542 - 63.
andYedavalli V. R. K N Ahmad 2001 Low Conservation of Functional Domains of HIV Type 1 vif and vpr Genes in Infected Mothers Correlates with Lack of Vertical Transmission. 17 10 911 923 - 64.
Zhang K F Rana C Silva J Ethier K Wehrly andB Chesebro C Power 2003 Human immunodeficiency virus type 1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity. 77 12 6899 6912 - 65.
Zhao L J. , L Wang andS Mukherjee O Narayan 1994 Biochemical Mechanism of HIV-1 Vpr Function: Oligomerization Mediated by the N-Terminal Domain. 269 51 32131 32137 - 66.
andZhou Y L Ratner 2000 Phosphorylation of Human Immunodeficiency Virus Type 1 Vpr Regulates Cell Cycle Arrest J. Virol.74 14 6520 6527